France’s INNOVAFEED raises €51 million while cutting 60 jobs: the paradox of industrial scale-up

While France’s insect protein industry is still reeling from the liquidation of Ynsect, Innovafeed has announced a €51 million funding round backed by its longstanding shareholders. At the same time, the company is preparing to cut around 60 jobs. Although the two announcements may appear contradictory, they primarily illustrate the transition of a deeptech company from a research-intensive phase to one focused on industrial operations and commercial development.

Innovafeed has secured €51 million in new funding from its existing shareholders, including Creadev, QIA, Temasek, ABC Impact, ADM and French Food Capital. At the same time, the company plans to eliminate around 60 positions, two-thirds of them at its historic site in Gouzeaucourt.

In an ecosystem where funding rounds are generally associated with recruitment and faster growth, this sequence may seem contradictory. It reflects the reality of a company that believes it has passed the riskiest stage of its development and is now reorganising its resources around its industrial operations.

For several years, Innovafeed and Ynsect have been the two leading French players in the insect protein sector. Both companies raised several hundred million euros to develop industrial capabilities on an unprecedented scale. But the difficulties encountered by Ynsect have profoundly changed the way the industry is perceived.

Investors no longer assess companies solely on their technological promises or theoretical production capacity. They are now looking for evidence of industrial execution and economic competitiveness.

This is precisely what Innovafeed is seeking to demonstrate. Since its previous funding round in 2022, the company says it has reached three major milestones: producing more than 15,000 tonnes of proteins and oils at its Nesle site, increasing output tenfold and reducing production costs by a factor of seven. Innovafeed also claims to have reached an industrial scale three times greater than that of the world’s second-largest player in the sector.

The company now believes it has demonstrated the robustness of its industrial platform. Its Nesle facility is described as fully operational and capable of producing competitive volumes.

From this perspective, the €51 million funding round is no longer intended to finance the construction of a new factory or the development of breakthrough technology. The company plans to use the capital to accelerate the commercial rollout of its Hilucia™ product ranges, develop new applications and continuously improve its industrial equipment.

This transition also explains the announced reorganisation. Over the past decade, Innovafeed has devoted substantial research and development resources to building its technology, optimising its processes and validating the performance of its products. The company is now ending its animal science R&D activities at the Gouzeaucourt site and partially transferring them to Nesle.

The move may appear paradoxical, but it is characteristic of many industrial companies as they mature. The skills required to invent a technology are not always the same as those needed to operate an industrial platform at scale. As processes stabilise, resources increasingly shift towards production, operational optimisation, logistics and commercial development.

For the insect protein industry, this transition may represent a more significant milestone than the funding round itself. After years spent convincing investors, building factories and demonstrating technological feasibility, the sector is entering a new phase: one in which it must prove that it can generate sustainable economic value.

From this perspective, Innovafeed’s €51 million funding round appears less like growth financing than a vote of confidence in an industrial model that believes it has passed its most important test: scaling up production.